CSIMarket
 


Durect Corp  (DRRX)
Other Ticker:  
 
 

DRRX's Net Cash Flow Growth by Quarter and Year

Durect's Net Cash Flow results by quarter and year




DRRX Net Cash Flow (in millions $) FY 2023 FY 2022 FY 2021 FY 2020
IV Quarter December - -6.91 -5.57 2.64
III Quarter September 7.23 3.26 -0.66 0.22
II Quarter June -7.54 -2.31 -1.47 -14.13
I Quarter March -4.19 -0.40 36.23 -2.35
FY   -4.51 -6.36 28.53 -13.62



DRRX Net Cash Flow third quarter 2023 Y/Y Growth Comment
Durect Corp achieved in the third quarter 2023, above Company average Net Cash Flow surge of 121.63% year on year, to $ 7.23 millions.

Looking into third quarter 2023 results within Major Pharmaceutical Preparations industry 18 other companies have achieved higher Net Cash Flow growth. While Durect Corp' s Net Cash Flow doubling of 121.63% ranks overall at the positon no. 277 in the third quarter 2023.




DRRX Net Cash Flow ( Y/Y Growth %) 2023
2022 2021 2020
IV Quarter December - - - -
III Quarter September 121.63 % - - -
II Quarter June - - - -
I Quarter March - - - -
FY   - - - -

Financial Statements
Durect's third quarter 2023 Net Cash Flow $ 7.23 millions DRRX's Income Statement
Durect's third quarter 2022 Net Cash Flow $ 3.26 millions Quarterly DRRX's Income Statement
New: More DRRX's historic Net Cash Flow Growth >>


DRRX Net Cash Flow (Quarter on Quarter Growth %)

2023
2022 2021 2020
IV Quarter December - - - 1100 %
III Quarter September - - - -
II Quarter June - - - -
I Quarter March - - 1272.35 % -
FY (Year on Year)   - - - -




Net Cash Flow third quarter 2023 Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #19
Healthcare Sector #49
Overall #277

Net Cash Flow Y/Y Growth Statistics
High Average Low
121.69 % -50.87 % -100 %
(Sep 30 2023)   (Sep 30 2018)
Net Cash Flow third quarter 2023 Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #19
Healthcare Sector #49
Overall #277
Net Cash Flow Y/Y Growth Statistics
High Average Low
121.69 % -50.87 % -100 %
(Sep 30 2023)   (Sep 30 2018)

Net Cash Flow by Quarter for the Fiscal Years 2020, 2021, 2022, 2023

Durect's Q/Q Net Cash Flow Growth


Net Cash Flow Q/Q Growth Statistics
High Average Low
0 % 0 % 0 %
 


DRRX's III. Quarter Q/Q Net Cash Flow Comment
III. Quarter 2023Seasonal Durect Corp in the factors net cash outflow of $ 7.23 millionsSeasonal factors appear to have contributed Durect Corp's restoration of positive trends, as DRRX postNet Cash Flow of $ 7.23 millions in the III. Quarter 2023 emerging from net cash outflow-7.54 millions in the second quarter. Durect Corp announced in the III. Quarter 2023 Net Cash Flow of $ 7.23 millions compare to net cash outflow recorded in previos quarter.

Within Major Pharmaceutical Preparations industry Durect Corp achieved highest sequential Net Cash Flow growth. While Durect's Net Cash Flow growth quarter on quarter, overall rank is .


Net Cash Flow Q/Q Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #
Healthcare Sector #
Overall #
Net Cash Flow Q/Q Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #
Healthcare Sector #
Overall #
Net Cash Flow Q/Q Growth Statistics
High Average Low
0 % 0 % 0 %
 


DRRX's III. Quarter Q/Q Net Cash Flow Comment
III. Quarter 2023Periodic Durect Corp in the influence net cash outflow of $ 7.23 millionsPeriodic influence appear to have contributed Durect Corp's rebound to recovery, as DRRX clinchesNet Cash Flow of $ 7.23 millions in the III. Quarter 2023 coming of net cash outflow-7.54 millions in the second quarter. Durect Corp announced in the III. Quarter 2023 Net Cash Flow of $ 7.23 millions compare to net cash outflow recorded in previos quarter.

Within Major Pharmaceutical Preparations industry Durect Corp achieved highest sequential Net Cash Flow growth. While Durect's Net Cash Flow growth quarter on quarter, overall rank is .


Durect's 12 Months Net Cash Flow Growth Year on Year


Net Cash Flow TTM Growth

12 Months Ending
(Sep 30 2023)
12 Months Ending
(Jun 30 2023)
12 Months Ending
(Mar 31 2023)
12 Months Ending
(Dec 31 2022)
12 Months Ending
(Sep 30 2022)
Cumulative Net Cash Flow 12 Months Ending $ -11.41 $ -15.38 $ -10.14 $ -6.36 $ -5.02
Y / Y Net Cash Flow Growth (TTM) - - - - -
Year on Year Net Cash Flow Growth Overall Ranking # # # # #
Seqeuential Net Cash Flow Change (TTM) - - - - -
Seq. Net Cash Flow Growth (TTM) Overall Ranking # # # # #




Cumulative Net Cash Flow growth Comment
Durect Corp' has realized cumulative trailing twelve months net cash outflow of $ -11 millions in the Sep 30 2023 period.

Durect Corp achieved highest trailing twelve month year on year Net Cash Flow growth. While overall Net Cash Flow growth ranking, remained unchanged compare to the previous quarter at no. .

Net Cash Flow TTM Q/Q Growth Statistics
High Average Low
0 %
0 %
0 %
 

Net Cash Flow TTM Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #
Healthcare Sector #
Overall #

Net Cash Flow TTM Y/Y Growth Statistics
High Average Low
0 %
0 %
0 %
 


Net Cash Flow TTM Q/Q Growth Company Ranking
Within: No.
Industry #
Sector #
S&P 500 #
Cumulative Net Cash Flow growth Comment
Durect Corp' has realized cumulative trailing twelve months net cash outflow of $ -11 millions in the Sep 30 2023 period.

Durect Corp achieved highest trailing twelve month year on year Net Cash Flow growth. While overall Net Cash Flow growth ranking, remained unchanged compare to the previous quarter at no. .

Net Cash Flow TTM Q/Q Growth Statistics
High Average Low
0 %
0 %
0 %
 


Net Cash Flow TTM Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #
Healthcare Sector #
Overall #

Net Cash Flow TTM Y/Y Growth Statistics
High Average Low
0 %
0 %
0 %
 


Net Cash Flow TTM Q/Q Growth Company Ranking
Within: No.
Industry #
Sector #
S&P 500 #




Other Net Cash Flow Growth
Major Pharmaceutical Preparations Industry Net Cash Flow Growth Trends and Statistics
Healthcare Sector Net Cash Flow Growth Statistics
Net Cash Flow Growth Trends for overall market
DRRX's Net Cash Flow Growth Ratio versus Major Pharmaceutical Preparations Industry, Healthcare Sector and total Market
Highest Ranking Net Cash Flow Growth
Lowest Ranking Net Cash Flow Growth
Net Cash Flow Growth for DRRX's Competitors
Net Cash Flow Growth for Durect's Suppliers
Net Cash Flow Growth for DRRX's Customers

You may also want to know
DRRX's Annual Growth Rates DRRX's Profitability Ratios DRRX's Asset Turnover Ratio DRRX's Dividend Growth
DRRX's Roe DRRX's Valuation Ratios DRRX's Financial Strength Ratios DRRX's Dividend Payout Ratio
DRRX's Roa DRRX's Inventory Turnover Ratio DRRX's Growth Rates DRRX's Dividend Comparisons



Companies with similar Net Cash Flow doubling for the quarter ending Sep 30 2023 within Healthcare SectorY/Y Change %Net Cash Flow for the quarter ending Sep 30 2023
Axogen inc 205.37%$ 205.366 millions
Amarin Corp Plcuk202.58%$ 202.576 millions
Trevena inc 175.52%$ 175.523 millions
Ikena Oncology Inc 173.39%$ 173.390 millions
Neurocrine Biosciences Inc 173.01%$ 173.006 millions
Aquestive Therapeutics Inc 160.06%$ 160.063 millions
Actavia Life Sciences Inc 151.37%$ 151.374 millions
Cytokinetics Incorporated146.32%$ 146.316 millions
Avanos Medical Inc 140.95%$ 140.952 millions
Lantheus Holdings Inc 134.62%$ 134.620 millions
Skye Bioscience Inc 125.55%$ 125.554 millions
Viridian Therapeutics Inc 122.74%$ 122.742 millions
Durect Corp121.69%$ 121.694 millions
Regeneron Pharmaceuticals Inc 118.81%$ 118.815 millions
Ensign Group Inc105.70%$ 105.703 millions
Vertex Pharmaceuticals Inc103.68%$ 103.679 millions
Tenaya Therapeutics Inc 96.61%$ 96.613 millions
Ainos Inc 94.42%$ 94.423 millions
Merck and Co Inc 93.77%$ 93.775 millions
Henry Schein Inc93.33%$ 93.333 millions
Insulet Corporation90.23%$ 90.226 millions
Benitec Biopharma Inc 87.53%$ 87.531 millions
Anika Therapeutics Inc 86.37%$ 86.373 millions
Cadre Holdings Inc 82.02%$ 82.025 millions
Vistagen Therapeutics Inc 73.30%$ 73.300 millions
Align Technology inc 72.35%$ 72.350 millions
Lftd Partners Inc 72.07%$ 72.074 millions
Tracon Pharmaceuticals Inc 64.12%$ 64.124 millions
Achari Ventures Holdings Corp I62.13%$ 62.129 millions
Acumen Pharmaceuticals Inc 60.96%$ 60.955 millions




Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com